Valiant Organics Limited (NSE: VALIANTORG | BSE: 540145)

By Raveendran R | Updated on:

Source: Valiant Organics Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026)

Metrics for FY 2025-26 Ended Mar 31, 2026
Profit & Loss (₹ Cr)
Revenue
₹738.76 Cr (▲ 2.8%)
Prev Year: ₹718.76 Cr
Gross Profit
₹301.38 Cr (▲ 15.2%)
Prev Year: ₹261.61 Cr
Operating Profit
₹55.53 Cr (▲ 109.2%)
Prev Year: ₹26.55 Cr
Net Profit
₹33.23 Cr (▲ N/M)
Prev Year: -₹3.43 Cr
Ratios & Margins (% / x)
Gross Margin
40.80 % (▲ 440 bps)
Prev Year: 36.40 %
Operating Margin
7.52 % (▲ 382 bps)
Prev Year: 3.69 %
PAT Margin
4.50 % (▲ 498 bps)
Prev Year: -0.48 %
ROCE
6.31 % (▲ 305 bps)
Prev Year: 3.26 %
ROCE (5Y Avg)
9.61 %
FY22–FY26 (5Y Avg)
ROE
4.38 % (▲ 485 bps)
Prev Year: -0.47 %
ROA
2.70 % (▲ 299 bps)
Prev Year: -0.29 %
Asset Turnover
0.60x (▼ 0.01 pts)
Prev Year: 0.61x
Balance Sheet (₹ Cr)
Total Assets
₹1,230.79 Cr (▲ 4.0%)
Prev Year: ₹1,182.93 Cr
Current Assets
₹352.23 Cr (▼ 1.1%)
Prev Year: ₹356.06 Cr
Total Liabilities
₹471.42 Cr (▲ 3.0%)
Prev Year: ₹457.66 Cr
Current Liabilities
₹350.25 Cr (▼ 5.0%)
Prev Year: ₹368.83 Cr
Total Debt
₹252.75 Cr (▲ 1.7%)
Prev Year: ₹248.46 Cr
Total Equity
₹759.37 Cr (▲ 4.7%)
Prev Year: ₹725.26 Cr
Working Capital
₹1.98 Cr (▲ N/M)
Prev Year: -₹12.77 Cr
Ratios & Margins (% / x)
Current Ratio
1.01x (▲ 0.04 pts)
Prev Year: 0.97x
Debt to Equity
0.33x (▼ 0.01 pts)
Prev Year: 0.34x
Debt to Assets
0.21x (- 0.00 pts)
Prev Year: 0.21x
Equity Multiplier
1.62x (▼ 0.01 pts)
Prev Year: 1.63x
Cash Flow (₹ Cr)
Operating Cash Flow
₹91.99 Cr (▲ 63.0%)
Prev Year: ₹56.43 Cr
CapEx
₹33.53 Cr (▲ 8.8%)
Prev Year: ₹30.83 Cr
Free Cash Flow
₹58.46 Cr (▲ 128.4%)
Prev Year: ₹25.60 Cr
Ratios & Margins (% / x)
FCF Margin
7.91 % (▲ 435 bps)
Prev Year: 3.56 %
Cash ROCE
10.45 % (▲ 352 bps)
Prev Year: 6.93 %
Cash ROE
12.11 % (▲ 433 bps)
Prev Year: 7.78 %
CF to Debt
0.36x (▲ 0.14 pts)
Prev Year: 0.23x

📋 Quick Facts: Company Snapshot

Attribute Disclosed Detail
Official Company Name Valiant Organics Limited
Corporate Identity Number (CIN) L24230MH2005PLC151348
ISIN INE565V01010
NSE Symbol & BSE Scrip Code NSE: VALIANTORG | BSE: 540145
Date of Incorporation / Founding Year 1984 (as Valiant Chemical Corporation); Incorporated as Private Limited in 2005; Converted to Public Limited in 2015
Founders / Key Founding Figures First-generation technocrats / Aarti Group Founders (Shri Chandrakant V. Gogri)
Registered Office 109, Udyog Kshetra, 1st Floor, Mulund-Goregaon Link Road, Mulund (West), Mumbai – 400080, Maharashtra, India
Corporate Headquarters 701-A, 7th Floor, Tower-B, Embassy 247, L.B.S. Road, Vikhroli (West), Mumbai – 400083, Maharashtra, India
Telephone & Investor Relations Contact +91 22 6797 6683 | Email: investor@valiantorganics.com
Chairperson of the Board Shri Navin C. Shah (Independent Director)
Managing Directors Shri Parimal H. Desai & Shri Sathiababu K. Kallada
Chief Financial Officer (CFO) Shri Mahek M. Chheda (Executive Director & CFO)
Company Secretary & Compliance Officer Shri Kaustubh B. Kulkarni
Promoter & Holding Group Aarti Group / Promoter Group
Industry / Sector Classification Speciality Chemicals & Pharmaceutical Intermediates
Total Permanent Workforce 908 permanent employees (as of March 31, 2026)
Manufacturing Infrastructure 6 manufacturing units across 5 Western India locations (Sarigam, Tarapur, Vapi, Jhagadia Unit 1 & 2, Ahmedabad)
Installed Production Capacity 80,000+ Metric Tonnes Per Annum (MTPA)
Geographic Reach India (Domestic 95% revenue share) and Global Export Markets (5% revenue share)
Statutory Auditors M/s. Gokhale & Sathe, Chartered Accountants
Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited (formerly Link Intime India Private Limited)

🏢 The Corporate Identity: Valiant Organics Overview, Promoters & History

The Big Picture: Business Model & Core Value Proposition

Valiant Organics Limited is a Mumbai-headquartered manufacturer of speciality chemicals and pharmaceutical intermediates. Established in 1984 by first-generation technocrats, the Company has scaled into a chemical manufacturing powerhouse featuring deep technical domain expertise across multiple specialized chemistries. Its core operating capabilities cover chlorination, ammonolysis, hydrogenation, acetylation, sulphonation, and methoxylation. The Company’s product portfolio serves vital applications across dyes and pigments, agrochemicals, pharmaceuticals, cosmetics, veterinary drugs, and specialty chemical value chains, with a strategic focus on products that drive domestic import substitution in India.

As an integral part of the Aarti Group ecosystem, Valiant Organics benefits from backward integration, shared process technology knowledge, and secure key raw material access. The Company operates multi-purpose, forward and backward-integrated manufacturing facilities equipped with automated process controls and Zero Liquid Discharge (ZLD) effluent treatment systems. Backed by dedicated research and quality control capabilities, Valiant Organics maintains international standards, enabling reliable process optimization, consistent batch quality, and responsive supply chain execution for its domestic and international customer base.

  • Core Industry Positions: One of the largest chlorophenol derivatives manufacturers globally; one of the largest domestic Para Nitro Aniline (PNA) and Para Amino Phenol (PAP) manufacturers; a leading domestic manufacturer of benzene derivatives; and one of the few commercial players in Ortho Anisidine and Para Anisidine.
  • Total Installed Capacity: Over 80,000 MTPA consolidated production capacity across 6 integrated manufacturing plants.
  • Environmental Footprint: 5 out of 6 manufacturing facilities operate as Zero Liquid Discharge (ZLD) units, with over 70% water recovery at its Jhagadia site.
  • Workforce Scale: 908 permanent employees across manufacturing locations and corporate administrative offices as of March 31, 2026.

The Founders, Promoters & Their Legacy

Valiant Organics was founded by technocrats with extensive operational experience in complex chemical transformations. The broader strategic direction of the Company is guided by the heritage of the Aarti Group of Companies. Shri Chandrakant V. Gogri, Chairman Emeritus and founder of the Aarti Group, is a key figure in the Indian chemical sector with decades of expertise in project execution, operational management, process development, and commercial strategy. His visionary leadership has been recognized through accolades including the Indian Chemical Council’s D. M. Trivedi Lifetime Achievement Award (2019) and the FICCI Chemical and Petrochemical Lifetime Contribution Award (2022).

The management team is led by Managing Directors Shri Parimal H. Desai and Shri Sathiababu K. Kallada, alongside Executive Directors Shri Mahek M. Chheda (CFO), Shri Nemin M. Savadia, and Shri Siddharth D. Shah. The technocrat-led executive team brings decades of collective domain expertise, overseeing process safety, yield enhancements, asset utilization, and strategic capital allocation across all operating units.

The Journey: Corporate History & Key Milestones

The evolution of Valiant Organics over four decades showcases a path of organic debottlenecking, product expansion, and strategic acquisitions:

  • 1984: Established as Valiant Chemical Corporation with a single product—Meta Chloroaniline.
  • 1997: Expanded product scope to include Chlorophenols for application in pharmaceutical intermediates, pesticides, disinfectants, and veterinary drugs.
  • 2005: Incorporated as a private limited company under the name Valiant Organics Private Limited.
  • 2008: Commenced international export operations.
  • 2013–2015: Expanded installed chlorophenols capacity from 3,000 MTPA to 4,800 MTPA; converted into a public limited company in 2015.
  • 2016–2018: Listed on the SME Board of the BSE in 2016; acquired Abhilasha Tex-Chem Limited in 2017 to add ammonolysis chemistry; received environmental clearance to expand chlorophenol capacity to 21,600 MTPA in 2018.
  • 2019: Amalgamated Amarjyot Chemicals Limited, adding large-scale hydrogenation, sulphonation, and nitration platforms with manufacturing facilities in Vapi, Jhagadia, and Ahmedabad.
  • 2020–2021: Migrated to the main board of BSE in 2020 and listed on NSE in 2021. Successfully completed backward integration for Ortho Nitro Anisole / Ortho Anisidine (ONA/OA) and commissioned Phase 1 of the 12,000 MTPA Para Amino Phenol (PAP) plant at Jhagadia Unit 2.
  • 2022–2024: Overcame PAP batch process operational constraints, ramping up production to over 400 MT per month; initiated operational debottlenecking, yield enhancements, and multi-purpose pharma intermediate plant development.
  • 2025–2026: Achieved turnaround in operational performance, driven by higher capacity utilization, process efficiency gains, yield improvements, and stabilization of the Jhagadia Unit 2 pharmaceutical intermediates complex.

The Corporate Umbrella & Group Structure

Valiant Organics operates as part of the broader Aarti Group alignment alongside group entities such as Aarti Industries Limited, Aarti Pharmalabs Limited, Aarti Surfactants Limited, and Aarti Drugs Limited. This corporate umbrella offers commercial synergies in raw material procurement, technical know-how sharing, and supply chain security. The corporate structure of Valiant Organics includes direct subsidiaries and step-down associate entities that complement its core chemistry focus:

  • Valiant Speciality Chemical Limited: 100% direct wholly-owned subsidiary incorporated in India.
  • Dhanvallabh Ventures LLP: 73.15% direct material subsidiary partnership firm.
  • Valiant Laboratories Limited (VLL): 46.84% indirect associate company (held through Dhanvallabh Ventures LLP). VLL successfully completed its IPO listing in October 2023.
  • Valiant Advanced Sciences Private Limited: Indirect associate company (100% subsidiary of Valiant Laboratories Limited).

⚙️ The Business Engine: Segments, Brands, Products & Operations

The Core Divisions & Segment Revenue Breakdown

The Company operates primarily across two reporting business divisions: the Speciality Chemical Division and the Pharma Division. The Speciality Chemical Division comprises chlorination, ammonolysis, hydrogenation, acetylation, methoxylation, and sulphonation platforms serving agrochemicals, dyes, pigments, and industrial applications. The Pharma Division focuses on pharmaceutical intermediates, predominantly Para Amino Phenol (PAP) manufactured at the Jhagadia Unit 2 facility.

Segment Name FY 2025-26 Revenue (₹ in Crores) % Share of Total Segment Revenue FY 2025-26 Segment Results / PBIT (₹ in Crores) Segment Assets (₹ in Crores) Segment Liabilities (₹ in Crores)
Speciality Chemical Division 574.82 77.81% 60.25 670.59 265.60
Pharma Division 163.94 22.19% (5.84) 558.41 219.54
Total Segment Reporting 738.76 100.00% 54.41 1,229.00 485.14
Unallocated Corporate Assets / Liabilities — — — 1.79 745.65
Consolidated Total 738.76 100.00% 54.41 1,230.79 1,230.79

The Product & Service Catalog (with Operational KPIs & Order Book)

Valiant Organics manages a production infrastructure with an aggregate installed capacity exceeding 80,000 MTPA across six specialized chemical processes. The portfolio spans diverse chemistries:

  • Chlorination (Sarigam Plant – 21,600 MTPA): Core products include Para ChloroPhenol (PCP), Ortho ChloroPhenol (OCP), 2,4 Di ChloroPhenol (2,4 DCP), 2,6 Di ChloroPhenol (2,6 DCP), and 2,4,6 Tri ChloroPhenol (2,4,6 TCP). Serves agrochemicals, cosmetics, veterinary drugs, and pharmaceuticals. Chlorination accounted for 26% of FY 2025-26 product revenues.
  • Ammonolysis (Tarapur & Vapi Plants – 16,600 MTPA Consolidated): Core products include Para Nitro Aniline (PNA) and Ortho Chloro Para Nitro Aniline (OCPNA), supplying dye and pigment manufacturers. Ammonolysis accounted for 20% of FY 2025-26 product revenues.
  • Hydrogenation & Methoxylation (Jhagadia Unit 1 – 28,800 MTPA): Manufactures Ortho Anisidine (OA), Para Anisidine (PA), IPPCA, Meta Chloro Aniline, Ortho Amino Phenol, and conversion derivatives. Hydrogenation represents the largest process platform, generating 48% of FY 2025-26 product revenues.
  • Hydrolysis & Hydrogenation (Jhagadia Unit 2 – 12,000 MTPA): Dedicated plant for Para Amino Phenol (PAP), a critical raw material intermediate for paracetamol production, providing import substitution against imports from China.
  • Acetylation, Sulphonation & Methoxylation (Ahmedabad Plant – 1,800 MTPA): Products include 6 Acetyl OAPSA, OT5SA, 4B Acid, 2B Acid, OA Acetanilide, and PA Acetanilide. Also performs contract job work. Other chemistries combined contributed 6% of FY 2025-26 revenues.

The Names You Know: Key Brands & Flagship Portfolio

Brand / Product Name Category / Business Segment Target Market & Key Positioning
Para Amino Phenol (PAP) Pharma Division / Hydrolysis & Hydrogenation Pharmaceutical Intermediates; key feedstock for Paracetamol manufacturing; domestic import substitution.
Chlorophenol Derivatives (PCP, OCP, 2,4 DCP) Speciality Chemical Division / Chlorination Agrochemicals & Disinfectants; leading global supplier position with automated ZLD production.
Para Nitro Aniline (PNA) Speciality Chemical Division / Ammonolysis Dyes & Pigments; key domestic supplier backed by Aarti Group PNCB raw material sourcing security.
Ortho Anisidine (OA) & Para Anisidine (PA) Speciality Chemical Division / Hydrogenation Speciality Dyes, Pigments & Pharma; niche commercial market presence with integrated methoxylation.
6 Acetyl OAPSA & OT5SA Speciality Chemical Division / Acetylation & Sulphonation Specialized Intermediates for textile dyes, pigments, and custom conversion job work.

Mapping the Domestic & Global Reach (India vs. Exports)

Valiant Organics commands a strong domestic market position across India while maintaining an export presence across key international markets in Asia, Europe, and the United States. Its manufacturing facilities in Western India are located near major ports (including Jawaharlal Nehru Port Trust and Hazira), optimizing export logistics and raw material handling.

Geographic Market FY 2025-26 Revenue (₹ in Crores) % Share of Revenue (FY 2025-26) FY 2024-25 Revenue (₹ in Crores) % Share of Revenue (FY 2024-25) Latest YoY (%)
Domestic (India) 698.96 94.61% 682.27 94.92% +2.45%
International (Exports) 39.80 5.39% 36.49 5.08% +9.07%
Total Revenue from Operations 738.76 100.00% 718.76 100.00% +2.78%

The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices

The Company operates six manufacturing facilities across five strategy locations in Western India:

  • Sarigam Facility (Gujarat): Installed capacity of 21,600 MTPA dedicated to chlorination chemistry (PCP, OCP, 2,4 DCP, 2,6 DCP, 2,4,6 TCP). Equipped with Zero Liquid Discharge (ZLD) systems and Agitated Thin Film Evaporators (ATFE).
  • Tarapur Facility (MIDC Boisar, Maharashtra): Installed capacity of 6,600 MTPA focused on ammonolysis chemistry (PNA). Features process automation (DCS) and automated emission monitoring.
  • Vapi Facility (GIDC Vapi, Gujarat): Installed capacity of 10,000 MTPA for ammonolysis chemistry (PNA, OCPNA). Features ZLD effluent treatment and process safety infrastructure.
  • Jhagadia Facility – Unit 1 (GIDC Jhagadia, Gujarat): Installed capacity of 28,800 MTPA dedicated to hydrogenation and methoxylation chemistries (OA, PA, IPPCA, conversion products). Features captive PSA nitrogen generation and high-pressure steam power recovery systems.
  • Jhagadia Facility – Unit 2 (GIDC Jhagadia, Gujarat): Installed capacity of 12,000 MTPA dedicated to hydrolysis and hydrogenation chemistries for Para Amino Phenol (PAP) and pharmaceutical intermediates. Features ZLD water recovery systems reusing ~70% of process water.
  • Ahmedabad Facility (GIDC Vatva, Gujarat): Installed capacity of 1,800 MTPA dedicated to acetylation, sulphonation, and methoxylation chemistries (6 Acetyl OAPSA, OT5SA, 4B Acid, 2B Acid). Operates ZLD with Agitated Thin Film Dryers (ATFD) and emission control scrubbers.

📊 The Financial Health: The Numbers Simplified

Multi-Year Financial Highlights (₹ in Crores)

Financial Metric FY 2025-26 FY 2024-25 FY 2023-24 FY 2022-23 FY 2021-22 Latest YoY (%)
Revenue from Operations 739 719 677 912 948 +2.78%
EBITDA 101 62 64 139 187 +62.90%
Profit After Tax (PAT) 33.23 3.43 (3.0) 76.00 103.00 +868.80%
Net Worth / Equity 583 522 583 588 585 +11.69%
Earnings Per Share (EPS in ₹) 12.26 (1.09) (1.09) 27.02 36.81 N/M
Return on Capital Employed (ROCE %) 6.31% 3.26% 4.50% 13.00% 21.00% –

Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)

Consolidated Statement of Profit & Loss Line Item FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Revenue from Operations 738.76 718.76 +2.78%
Other Income 6.92 8.78 -21.18%
Total Income 745.68 727.54 +2.49%
Cost of Materials Consumed 441.66 440.07 +0.36%
Purchases of Stock-in-Trade 1.94 12.62 -84.63%
Changes in Inventories of Finished Goods, WIP and Stock-in-Trade (6.22) 4.46 N/M
Employee Benefits Expense 48.86 44.99 +8.60%
Finance Costs 18.20 24.05 -24.32%
Depreciation and Amortization Expense 39.56 35.76 +10.63%
Other Expenses 164.35 162.68 +1.03%
Total Expenses 708.35 724.63 -2.25%
EBITDA 95.10 62.73 +51.60%
Profit before Finance Costs and Tax (EBIT) 55.53 26.55 +109.15%
Profit / (Loss) Before Exceptional Items and Tax 37.33 2.91 +1182.82%
Share of Profit / (Loss) of Associates (1.12) (0.76) +47.37%
Exceptional Items 5.72 — –
Profit / (Loss) Before Tax 41.93 2.15 +1850.23%
Earlier Years Tax Adjustments (2.53) 0.20 N/M
Deferred Tax Expense 11.23 5.38 +108.74%
Net Profit / (Loss) for the Period (PAT) 33.23 (3.43) N/M
Profit Attributable to Owners of the Company 33.24 (3.74) N/M
Profit Attributable to Non-Controlling Interest (0.01) 0.31 N/M
Other Comprehensive Income (Net of Tax) 0.05 (0.95) N/M
Total Comprehensive Income for the Period 33.27 (4.38) N/M
Basic EPS (₹) 11.86 (1.24) N/M
Diluted EPS (₹) 11.86 (1.24) N/M

Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)

Consolidated Balance Sheet Line Item As at March 31, 2026 (₹ in Crores) As at March 31, 2025 (₹ in Crores) Latest YoY (%)
ASSETS
Non-Current Assets
Property, Plant and Equipment 679.05 643.74 +5.49%
Capital Work-in-Progress (CWIP) 21.16 65.70 -67.79%
Right of Use Assets 3.20 0.30 +966.67%
Other Intangible Assets 0.35 0.45 -22.22%
Goodwill on Consolidation 12.33 12.33 0.00%
Non-Current Investments 150.54 93.58 +60.87%
Other Non-Current Financial Assets 6.41 5.68 +12.85%
Other Non-Current Assets 5.53 5.09 +8.64%
Total Non-Current Assets 878.57 826.87 +6.25%
Current Assets
Inventories 91.52 88.97 +2.87%
Trade Receivables 243.31 176.89 +37.55%
Cash and Cash Equivalents 1.79 7.10 -74.79%
Bank Balances Other than Cash & Cash Equivalents 0.35 0.55 -36.36%
Loans (Current) 0.66 49.19 -98.66%
Other Current Financial Assets 3.60 5.51 -34.66%
Current Tax Assets (Net) 3.12 12.13 -74.28%
Other Current Assets 7.86 15.73 -50.03%
Total Current Assets 352.23 356.06 -1.08%
TOTAL ASSETS 1,230.79 1,182.93 +4.05%
EQUITY AND LIABILITIES
Equity
Equity Share Capital 28.02 28.00 +0.07%
Other Equity 731.36 697.26 +4.89%
Non-Controlling Interest (NCI) (0.01) 0.00 N/M
Total Equity (Net Worth) 759.37 725.26 +4.70%
Non-Current Liabilities
Non-Current Borrowings 52.65 50.69 +3.87%
Non-Current Lease Liabilities 2.61 0.13 +1907.69%
Other Non-Current Financial Liabilities 17.34 1.41 +1129.79%
Non-Current Provisions 2.92 2.21 +32.13%
Deferred Tax Liabilities (Net) 45.65 34.39 +32.74%
Total Non-Current Liabilities 121.17 88.83 +36.41%
Current Liabilities
Current Borrowings 200.10 197.77 +1.18%
Current Lease Liabilities 0.54 0.19 +184.21%
Trade Payables (MSME Dues) 9.28 7.84 +18.37%
Trade Payables (Other than MSME) 112.81 140.84 -19.90%
Other Current Financial Liabilities 17.44 15.81 +10.31%
Other Current Liabilities 5.04 1.68 +200.00%
Current Provisions 5.05 4.69 +7.68%
Total Current Liabilities 350.25 368.83 -5.04%
TOTAL EQUITY AND LIABILITIES 1,230.79 1,182.93 +4.05%

Cash Flow: Tracking the Money Movement

Consolidated Cash Flow Statement Summary FY 2025-26 (₹ in Crores) FY 2024-25 (₹ in Crores) Latest YoY (%)
Profit Before Tax 41.93 2.15 +1850.23%
Adjustments for Non-Cash / Non-Operating Items 54.01 56.35 -4.15%
Operating Profit Before Working Capital Changes 95.95 58.50 +64.02%
Working Capital Adjustments (6.49) (2.07) +213.53%
Direct Taxes Paid / Refunded (Net) 2.53 — –
Net Cash Flow from Operating Activities (A) 91.99 56.43 +63.02%
Purchase of Property, Plant and Equipment (CapEx / CWIP) 33.53 30.83 +8.76%
Proceeds from Sale of Fixed Assets 6.31% 3.26% –
Interest Received 3.66 2.17 +68.66%
Dividend Received 0.01 0.01 0.00%
Net Investment in Subsidiaries and Other Entities (56.96) 1.71 N/M
Sale of Investments — 4.66 –
Bank Balances Not Considered as Cash Equivalents 0.20 (0.19) N/M
Net Cash Used in Investing Activities (B) (86.22) (20.96) +311.35%
Proceeds from Issue of Share Capital & Share Premium 6.31% 3.26% –
Interest & Finance Charges Paid (18.20) (23.64) -23.01%
Net Short-Term Borrowing Availment / Repayment 2.33 15.47 -84.94%
Proceeds / (Repayments) of Long-Term Borrowing 6.31% 3.26% –
Payment of Lease Liabilities (2.82) (0.19) +1384.21%
Net Cash Used in Financing Activities (C) (11.07) (31.81) -65.20%
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C) (5.30) 3.66 N/M
Cash & Cash Equivalents at the Beginning of the Year 7.10 3.44 +106.40%
Cash & Cash Equivalents at the End of the Year 1.79 7.10 -74.79%

Funding the Future: CapEx, CWIP & R&D Spending

Valiant Organics maintained disciplined capital allocation during FY 2025-26, prioritizing debottlenecking, operational yield improvements, and brownfield modifications over large greenfield expansions. Capital work-in-progress (CWIP) reduced from ₹65.70 Crores as of March 31, 2025, to ₹21.16 Crores as of March 31, 2026, reflecting the successful capitalization and commissioning of key processing units, including the Jhagadia Unit 2 pharmaceutical intermediates development projects.

Research and Development (R&D) efforts focused on process optimization, solvent recovery, yield enhancements, and impurity profiling for pharma intermediates. R&D expenditure for FY 2025-26 stood at approximately ₹0.53 Crores compared to approximately ₹0.06 Crores in FY 2024-25, highlighting an intensified technical push toward higher-value chemistry applications.

👥 Power & Control: Corporate Governance, Leadership & Ownership

The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)

Name of Director / KMP Designation / Role DIN Category
Shri Navin C. Shah Chairperson & Independent Director 01415556 Non-Executive, Independent Director
Shri Parimal H. Desai Managing Director 00009272 Executive Director
Shri Sathiababu K. Kallada Managing Director 02107652 Executive Director
Shri Mahek M. Chheda Executive Director & Chief Financial Officer 06763870 Executive Director (KMP)
Shri Nemin M. Savadia Executive Director 00128256 Executive Director
Shri Siddharth D. Shah Executive Director 07263018 Executive Director
Dr. Kiritkumar H. Desai Non-Executive Director 08610595 Non-Executive Non-Independent Director
Shri Santosh S. Vora Non-Executive Director 07633923 Non-Executive Non-Independent Director
Smt. Sonal A. Vira Independent Director 09505883 Non-Executive, Independent Director
Dr. Sudhirprakash B. Sawant Independent Director 02343218 Non-Executive, Independent Director
Shri Paras S. Savla Independent Director 10773507 Non-Executive, Independent Director
Shri Kaustubh B. Kulkarni Company Secretary & Compliance Officer M. No. A52980 Key Managerial Personnel (KMP)

Who Owns the Stock? Shareholding Pattern

The shareholding structure of Valiant Organics as of March 31, 2026, comprising a total issued, subscribed, and paid-up share capital of ₹ 28,01,96,100 divided into 2,80,19,610 fully paid-up equity shares of face value ₹ 10 each:

Category of Shareholder Number of Equity Shares Held % Shareholding (March 31, 2026)
Promoters & Promoter Group 1,06,17,174 37.89%
Foreign Portfolio Investor Category I 79,103 0.28%
Central Government / State Government 300 0.00%
Directors & Relatives (excluding Independent/Nominee) 55,63,972 19.86%
Promoter Group Trusts 1,95,882 0.70%
Resident Individuals (Nominal Capital up to ₹0.0200 Crores) 60,92,175 21.74%
Resident Individuals (Nominal Capital in excess of ₹0.0200 Crores) 42,34,970 15.11%
Non Resident Indians (NRIs) 2,38,808 0.85%
Bodies Corporate 5,45,071 1.95%
Others / Cleared Members / HUF 4,52,155 1.61%
Total Public Shareholding 1,74,02,436 62.11%
Total Shareholding 2,80,19,610 100.00%

🗺️ The Corporate Family Tree: Group Structure & Strategic Investments

Subsidiaries, Associates, & Joint Ventures (Form AOC-1)

Entity Name Corporate Relationship Country % Shareholding / Contribution FY 2025-26 Turnover / Income (₹ in Crores) FY 2025-26 Profit / (Loss) After Tax (₹ in Crores)
Valiant Speciality Chemical Limited Direct Wholly-Owned Subsidiary India 100.00% 0.01 (0.00)
Dhanvallabh Ventures LLP Direct Material Subsidiary India 73.15% 0.38 (0.03)
Valiant Laboratories Limited (VLL) Indirect Associate Company (via Dhanvallabh Ventures LLP) India 46.84% (319.76) (5.54)
Valiant Advanced Sciences Private Limited Indirect Associate Company (Wholly-owned subsidiary of VLL) India 46.84% (Indirect) (156.18) (8.81)

Strategic Investments & Treasury Holdings

Valiant Organics maintains a strategic treasury portfolio encompassing equity and preference share holdings in Aarti Group companies, clean energy special purpose vehicles (SPVs), and local industrial infrastructure cooperatives. Total non-current financial investments stood at ₹150.54 Crores as of March 31, 2026 (compared to ₹93.58 Crores as of March 31, 2025):

  • Aarti Industries Limited: 30,000 equity shares (Fair Value ₹0.01 Crores).
  • Aarti Pharmalabs Limited: 7,500 equity shares (Fair Value ₹0.44 Crores).
  • Aarti Surfactants Limited: 20,240 4% Redeemable Preference Shares (Fair Value ₹0.43 Crores).
  • Renew Green (GJ Six) Private Limited: 25,30,000 equity shares (Cost ₹2.53 Crores) representing a 26% stake for captive renewable power sourcing.
  • Pro-Zeal Green Power Eight Private Limited: 63,000 equity shares (Cost ₹0.06 Crores) representing a 26.25% stake in a renewable energy project SPV. Additionally, subscribed to 11,364 Compulsory Convertible Debentures (CCDs) of ₹ 1,000 each in April 2026.
  • Narmada Clean Tech: 26,610 equity shares (Book Value ₹0.0266 Crores) held for industrial effluent handling infrastructure.
  • Valiant Laboratories Limited (via Dhanvallabh Ventures LLP): 2,54,37,500 equity shares carrying an aggregate equity-method investment value of ₹1.46 Crores.

🎯 The Strategic Outlook: Competitive Moats, Risks & Future Growth Plans

Competitive Advantages & Economic Moats

Valiant Organics holds several core competitive advantages that underpin its market presence in the Indian speciality chemicals sector:

  • Dominant Market Positions & Scale Moat: One of the world’s largest chlorophenol derivative producers and the sole domestic producer in India; a leading domestic manufacturer of Para Nitro Aniline (PNA); and an early domestic commercial producer of Para Amino Phenol (PAP) for paracetamol manufacturing.
  • Integrated Sourcing & Aarti Group Synergies: Raw material integration with Aarti Industries Limited for key building blocks like PNCB secures raw material availability, lowers freight overheads, and shields production scheduling from overseas supply chain shocks.
  • Multi-Process Technological Breadth: Deep process chemistry capabilities across chlorination, ammonolysis, hydrogenation, methoxylation, acetylation, and sulphonation enable flexible batch scheduling, rapid product mix adjustments, and contract manufacturing execution.
  • Environmental Compliance & ZLD Barrier: Operating five Zero Liquid Discharge (ZLD) plants with advanced effluent treatment infrastructure provides a significant compliance buffer against stringent environmental regulations, creating a barrier to entry for smaller unorganized competitors.
  • Strategic Location Advantage: Manufacturing plants situated in major chemical belts of Gujarat (Sarigam, Vapi, Jhagadia, Ahmedabad) and Maharashtra (Tarapur) near western Indian ports ensure lower outbound logistics costs and faster delivery timelines.

What Could Go Wrong? Key Challenges & Business Risks

The management has identified several operational and external risk factors that could impact future operating performance:

  • Chinese Supply Dynamics & Price Volatility: Excess manufacturing capacity in China across commodity intermediates can create pricing pressure and margin volatility in domestic and export markets.
  • End-User Cyclicality: Demand fluctuations across downstream sectors—specifically agrochemicals, textile dyes, and pigments—can impact capacity utilization and volume absorption.
  • Raw Material & Energy Price Fluctuations: Volatility in crude oil, basic benzene derivatives, natural gas, and coal prices affects input economics.
  • Environmental Regulatory Compliance Costs: Evolving regulatory standards require continuous capital expenditure on waste treatment, emission controls, and safety systems.
  • Foreign Exchange Risk: Unhedged exposure to foreign currency fluctuations in exports and imported raw materials can influence net realisations, managed through natural hedging and forward contracts.

The Next Chapter: Growth, Order Pipeline & CapEx Initiatives

Moving into FY 2026-27, Valiant Organics is directing its strategic priorities toward maximizing value from existing installed assets rather than embarking on capital-intensive greenfield investments:

  • Jhagadia Unit 2 Stabilization: Scaling up operations and yields at the 12,000 MTPA Para Amino Phenol (PAP) unit and expanding the pharmaceutical intermediates portfolio to supply domestic pharma manufacturers.
  • Operational Debottlenecking: Executing brownfield debottlenecking, equipment upgrades, continuous process conversions (such as phenol chlorination continuous processing), and automation (DCS systems) at Vapi and Sarigam facilities.
  • Import Substitution & Product Diversification: Developing custom molecules and specialized derivatives based on chlorination, ammonolysis, and hydrogenation platforms to serve non-cyclical end-user industries.
  • Renewable Energy & Cost Leadership: Expanding renewable energy sourcing through equity investments in solar/wind SPVs (Pro-Zeal Green Power Eight) and leveraging captive steam-based power generation to reduce energy costs per tonne.
  • Reorganization & Synergies: Evaluating potential corporate restructuring options involving subsidiaries and associate entities to streamline business architecture, achieve operational synergies, and unlock shareholder value.

The Verdict: Strategic Outlook & Conclusion

FY 2025-26 marked a operational turnaround for Valiant Organics Limited. Through operational recalibration, yield enhancements, cost control, and stabilization of its pharmaceutical intermediates business, the Company returned to profitability with EBITDA expanding 63.1% to ₹ 100.80 Crore and Profit Before Tax reaching ₹ 34.40 Crore. Supported by an upgraded credit outlook from CRISIL (revised from ‘Negative’ to ‘Stable’ at ‘CRISIL A-/Stable’ in August 2026), secure raw material linkages, multi-process engineering expertise, and established market leadership across core chemistries, Valiant Organics is positioned to capitalize on India’s expanding speciality chemicals and pharmaceutical intermediate sectors.

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.valiantorganics.com

Note on Calculations: Percentage shares, consolidated subtotals, ratios, and YoY percentage changes presented across the profile and financial tables were calculated directly using the financial figures disclosed in the Valiant Organics Limited Annual Report FY 2025-26.